$EYPT earnings report

EyePoint reports Q3 2026 net loss of $(95,612) thousand, or $(1.07) per share, as Phase 3 wet AMD program is concluded and workforce is cut about 53%. AlphAI read EyePoint's Q3 FY2026 filing as weak. 2 quarters are on record below.

Q3 FY2026

AlphAI · Earnings readEYPT · Q3 2026 · ended 2026-09-30

EyePoint reports Q3 2026 net loss of $(95,612) thousand, or $(1.07) per share, as Phase 3 wet AMD program is concluded and workforce is cut about 53%

↓Weak quarter

Total revenues were $756 thousand against $966 thousand a year earlier, operating expenses rose to $97,633 thousand from $62,991 thousand, and the company reports cash, cash equivalents and marketable securities of $118 million. The Phase 3 LUGANO and LUCIA wet AMD trials did not achieve their primary endpoints, the wet AMD program is being wound down, and the filing states the cash runway extends only into late third quarter of 2027, with going-concern uncertainty listed among risks.

Revenue
$756K
Product sales, net
$528K

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total revenues (three months ended Sept 30, 2026)GAAP$756K––
Product sales, net (three months)GAAP$528K––
License and collaboration agreements (three months)GAAP$49K––
Royalty income (three months)GAAP$179K––
Cost of sales (three months)GAAP$523K––
Research and development (three months)GAAP$81.67M––
Sales and marketing (three months)GAAP$31K––
General and administrative (three months)GAAP$15.41M––
Total operating expenses (three months)GAAP$97.63M––
Loss from operations (three months)GAAP−$96.88M––
Interest and other income, net (three months)GAAP$1.26M––
Net loss before provision for income taxes (three months)GAAP−$95.61M––
Provision for income taxes (three months)GAAP—––
Net loss (three months)GAAP−$95.61M––
Net loss per common share, basic and diluted (three months)GAAP$(1.07)––
Total revenues (nine months ended Sept 30, 2026)GAAP$1.96M––
Product sales, net (nine months)GAAP$995K––
License and collaboration agreements (nine months)GAAP$695K––
Royalty income (nine months)GAAP$269K––
Cost of sales (nine months)GAAP$1.06M––
Research and development (nine months)GAAP$237.4M––
Sales and marketing (nine months)GAAP$65K––
General and administrative (nine months)GAAP$44.89M––
Total operating expenses (nine months)GAAP$283.4M––
Loss from operations (nine months)GAAP−$281.5M––
Interest and other income, net (nine months)GAAP$6.52M––
Net loss before provision for income taxes (nine months)GAAP−$275.0M––
Provision for income taxes (nine months)GAAP$50K––
Net loss (nine months)GAAP−$274.9M––
Net loss per common share, basic and diluted (nine months)GAAP$(3.15)––
Cash, cash equivalents and marketable securities (as of Sept 30, 2026)other$118M––

Segments

SegmentRevenueq/qy/y
Product sales, netNo driver stated in the filing.$528K––
License and collaboration agreementsNo driver stated in the filing.$49K––
Royalty incomeNo driver stated in the filing.$179K––

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • The filing states that the company raised an additional $10 million after quarter-end under its at-the-market equity facility.

What drove it

  • The company attributes the increase in operating expenses for the quarter primarily to ongoing DURAVYU Phase 3 clinical trials for wet AMD and DME.
  • Research and development expense for the quarter was $81,670 thousand compared with $47,754 thousand a year earlier.
  • Following the LUCIA results, the Board approved a strategic prioritization focused on the late-stage DME program, with an approximately 53% workforce reduction and associated operational adjustments.
  • The company estimates these actions will generate approximately $30 million in annualized savings.
  • Phase 3 LUGANO (announced August 17, 2026) did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label 2 mg aflibercept in the full analysis population.
  • Phase 3 LUCIA (announced October 19, 2026) did not achieve the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label 2 mg aflibercept in the full analysis population.
  • The company will conclude the wet AMD program before completion of the full second year of the Phase 3 LUGANO and LUCIA studies, while allowing additional patients to complete year two to support the safety database for a potential DME new drug application.
  • Phase 3 COMO and CAPRI DME trials are reported as fully enrolled with over 550 patients, with topline data expected early in the fourth quarter of 2027.

Concerns

  • Net loss widened to $(95,612) thousand from $(59,732) thousand, and nine-month net loss was $(274,914) thousand against $(164,353) thousand.
  • Revenue is minimal: total revenues were $756 thousand for the quarter and $1,959 thousand for the nine months, against $30,751 thousand in the prior-year nine months, which included license and royalty income.
  • Cash, cash equivalents and marketable securities fell to $118 million from $306 million at December 31, 2025, and the company reports a cash runway only into late third quarter of 2027.
  • The forward-looking statements section lists uncertainty regarding the company's ability to continue as a going concern.
  • The forward-looking statements section lists the company's ability to comply with Nasdaq's minimum bid compliance requirement as a risk.
  • The forward-looking statements section lists uncertainties regarding the FDA warning letter pertaining to the Watertown, MA manufacturing facility.
  • The company may incur additional costs in connection with its strategic prioritization not currently contemplated, according to the forward-looking statements section.

What to watch

  • Topline data from Phase 3 COMO and CAPRI DME trials, expected early in the fourth quarter of 2027.
  • Execution of the workforce reduction and whether the approximately $30 million annualized savings are realized as estimated.
  • Progress on business development, financing and other cost reduction opportunities that the company says could extend the cash runway.
  • Additional analyses of LUGANO, LUCIA and pooled Phase 3 data, which the company says will assess next steps for wet AMD.
  • Use of the at-the-market equity facility following the additional $10 million raised after quarter-end.
  • Resolution of the FDA warning letter relating to the Watertown, MA manufacturing facility.
  • Nasdaq minimum bid compliance status.

Balance sheet and cash flow

  • Cash, cash equivalents and marketable securities were $118 million as of September 30, 2026, compared with $306 million as of December 31, 2025.
  • Balance sheet at September 30, 2026: cash and cash equivalents $83,206 thousand; marketable securities $35,007 thousand; total current assets $126,986 thousand; total assets $166,137 thousand; total liabilities $57,631 thousand; total stockholders' equity $108,506 thousand.
  • Balance sheet at December 31, 2025: cash and cash equivalents $101,821 thousand; marketable securities $204,265 thousand; total assets $363,996 thousand; total stockholders' equity $306,113 thousand.
  • The company states that cash at September 30, 2026, together with the additional $10 million raised after quarter-end under its at-the-market facility and anticipated operational adjustments, will enable it to fund operations into late third quarter of 2027.
  • The company states it continues to pursue business development, financing and other cost reduction opportunities that could further extend the cash runway.
  • No operating cash flow or free cash flow figures are reported in the filing.

Analysis

EyePoint reported a third quarter 2026 GAAP net loss of $(95,612) thousand, or $(1.07) per share, against a net loss of $(59,732) thousand, or $(0.85) per share, a year earlier. Total revenues were $756 thousand, compared with $966 thousand, and the three product and royalty lines in the statement of operations were each lower than in the prior-year quarter. Operating expenses rose to $97,633 thousand from $62,991 thousand. Research and development expense accounts for most of the increase, moving to $81,670 thousand from $47,754 thousand, and the company attributes the rise primarily to the ongoing DURAVYU Phase 3 trials for wet AMD and DME. General and administrative expense was $15,409 thousand against $14,490 thousand.

The nine-month figures show the same pattern at a larger scale. Nine-month total revenues were $1,959 thousand against $30,751 thousand, and the prior-year period included license and collaboration revenue of $16,531 thousand and royalty income of $12,923 thousand, which were $695 thousand and $269 thousand in 2026. Nine-month research and development expense reached $237,427 thousand against $161,825 thousand, and the nine-month net loss was $(274,914) thousand. The filing does not print a gross margin figure, and cost of sales is reported as a line item only.

The balance sheet shows cash, cash equivalents and marketable securities of $118 million at September 30, 2026, against $306 million at December 31, 2025. Total stockholders' equity fell to $108,506 thousand from $306,113 thousand. The company states that this balance, together with a further $10 million raised after quarter-end under its at-the-market facility and anticipated operational adjustments, will fund operations into late third quarter of 2027. The filing reports no share repurchases or dividends.

The filing's central disclosures concern the clinical program. The Phase 3 LUGANO trial in wet AMD (August 17, 2026) and the Phase 3 LUCIA trial (October 19, 2026) each did not meet the primary endpoint of statistical non-inferiority in mean change in BCVA versus on-label 2 mg aflibercept in the full analysis population. The company will conclude the wet AMD program before the full second year of both studies and has moved resources to the DME program, where Phase 3 COMO and CAPRI are fully enrolled with over 550 patients and topline data are expected early in the fourth quarter of 2027. The company estimates the workforce reduction of about 53% will produce roughly $30 million in annualized savings. The CFO states that the company intends to pursue further levers to extend its financial runway.

For the reader, the points that merit attention are the narrow cash runway relative to the timing of DME topline data, the going-concern uncertainty and Nasdaq minimum bid compliance that the forward-looking statements section lists as risks, and the FDA warning letter tied to the Watertown facility. The filing gives no guidance figures, so there is no outlook to compare against.

Management, verbatim

“Capital discipline is now one of our highest priorities,”

George O. Elston, Executive Vice President and Chief Financial Officer

The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56, along with a favorable safety profile that included every six-month redosing.

Jay S. Duker, M.D., President and Chief Executive Officer

Not in the filing

stated, not guessed
  • Gross margin percentage is not printed in the filing.
  • Percentage changes year over year for revenue, operating expenses and net loss are not printed.
  • Prior-quarter (Q2 2026) figures are not printed in the filing.
  • Segment-level prior-year and prior-quarter revenue figures are not printed.
  • Operating cash flow and free cash flow are not reported.
  • Financial guidance figures are not provided; the filing gives only a cash runway statement.
  • Prior-year and prior-quarter comparison for cash, cash equivalents and marketable securities on a quarter basis is not printed; the $306 million comparison is as of December 31, 2025.
  • Repurchases and dividends are not reported.
  • Amount of the at-the-market facility and the terms of the $10 million raise are not printed beyond the stated amount.
  • Share price reaction and analyst consensus estimates are not provided.
  • The previous outlook covered cash runway and clinical data timing only, with no revenue or expense guidance for the third quarter of 2026 to compare against.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

second quarter 2026

AlphAI · Earnings readEYPT · second quarter 2026 · ended June 30, 2026

EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments

→Mixed quarter

Revenue declined, operating expenses and net loss increased, and cash and investments declined from March 31, 2026, while pivotal wet AMD and DME programs advanced toward stated enrollment and data milestones.

Revenue
$500K
EPS · other
($1.09)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Total net revenueother$500K––
Operating expensesother$97.9M––
Net non-operating incomeother$2.9M––
Net lossother$94.5M––
Net loss per shareother($1.09) per share––
Cash, cash equivalents, and marketable securitiesother$180M––

into the fourth quarter of 2027 outlook

  • NoteCash, cash equivalents, and marketable securities as of June 30, 2026, will enable the Company to fund operations into the fourth quarter of 2027 beyond key milestones for the Phase 3 wet AMD program in 2026.
  • NoteTopline data readout for LUGANO expected in August 2026.
  • NoteLUCIA topline data results are expected in the fourth quarter of 2026.
  • NoteTopline data for both DME trials are anticipated in the fourth quarter of 2027.

What drove it

  • The decrease in total net revenue was primarily driven by recognition of remaining deferred revenue related to the Company’s 2023 agreement for the license of YUTIQ product rights.
  • The increase in operating expenses was primarily attributable to ongoing DURAVYU Phase 3 clinical trials for wet AMD and DME and scale-up of the commercial manufacturing facility.
  • Pivotal Phase 3 COMO and CAPRI DME trials completed enrollment, together enrolling over 480 patients in five months.
  • A May 2026 Data Safety Monitoring Committee meeting recommended that LUGANO and LUCIA continue as planned with no protocol modifications.

Concerns

  • Total net revenue was $0.5 million compared to $5.3 million for the corresponding period in 2025.
  • Operating expenses totaled $97.9 million versus $67.6 million for the corresponding period in 2025.
  • Net loss was $94.5 million, or ($1.09) per share, compared to a net loss of $59.4 million, or ($0.85) per share, for the corresponding period in 2025.
  • Cash, cash equivalents, and marketable securities totaled $180 million as of June 30, 2026, compared to $223 million as of March 31, 2026.
  • DURAVYU is an investigational product and has not been approved by the FDA.

What to watch

  • Topline data readout for the pivotal Phase 3 LUGANO wet AMD trial expected in August 2026.
  • LUCIA pivotal Phase 3 wet AMD topline data expected in the fourth quarter of 2026.
  • Topline data for the Phase 3 COMO and CAPRI DME trials anticipated in the fourth quarter of 2027.
  • Cash runway expected into the fourth quarter of 2027.

Balance sheet and cash flow

  • Cash, cash equivalents, and marketable securities as of June 30, 2026, totaled $180 million compared to $223 million as of March 31, 2026.
  • The Company expects cash, cash equivalents, and marketable securities as of June 30, 2026, to fund operations into the fourth quarter of 2027.

Analysis

EyePoint reported total net revenue of $0.5 million for the second quarter ended June 30, 2026, compared to $5.3 million for the corresponding period in 2025. The company attributed the decrease primarily to recognition of remaining deferred revenue associated with its 2023 license agreement for YUTIQ product rights. The filing does not report product-level or segment revenue, leaving limited visibility into recurring revenue sources.

Operating expenses totaled $97.9 million versus $67.6 million for the corresponding period in 2025, driven primarily by ongoing DURAVYU Phase 3 trials in wet AMD and DME and scale-up of the commercial manufacturing facility. Net non-operating income totaled $2.9 million. Net loss was $94.5 million, or ($1.09) per share, compared with a net loss of $59.4 million, or ($0.85) per share, for the corresponding period in 2025.

The company ended June 30, 2026 with $180 million of cash, cash equivalents, and marketable securities, compared with $223 million as of March 31, 2026. Management stated that cash, cash equivalents, and marketable securities as of June 30, 2026 are expected to fund operations into the fourth quarter of 2027, beyond key Phase 3 wet AMD milestones in 2026. The filing did not report operating cash flow, free cash flow, debt, or capital-return activity.

Clinical execution is the central near-term focus. LUGANO topline data are expected in August 2026 and LUCIA topline results are expected in the fourth quarter of 2026. The two identical wet AMD non-inferiority trials versus on-label aflibercept enrolled over 900 patients. For DME, COMO and CAPRI completed enrollment, together enrolling over 480 patients in five months, with topline data anticipated in the fourth quarter of 2027.

The May 2026 DSMC meeting recommended that LUGANO and LUCIA continue as planned with no protocol modifications, and the company said interim masked Phase 3 safety data remained consistent with favorable safety in four previously completed DURAVYU clinical trials in over 190 patients, with no drug-related safety concerns. The upcoming wet AMD readouts are the principal stated clinical milestones, while higher operating expenses, the larger net loss, lower cash balances, and the absence of current recurring revenue growth remain key financial considerations.

Management, verbatim

With topline data from our pivotal Phase 3 LUGANO wet AMD trial expected this month, followed by LUCIA in the fourth quarter, and enrollment now completed in our pivotal Phase 3 DME program, we continue to execute across our clinical programs.

Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint

The LUGANO and LUCIA data readouts represent transformative advancement in the wet AMD landscape, potentially positioning DURAVYU as the foundational treatment option for sustained patient care.

Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint

Not in the filing

stated, not guessed
  • Gross profit
  • Gross margin
  • Operating income or loss
  • GAAP designation for reported financial metrics
  • Non-GAAP financial metrics and reconciliations
  • Prior-quarter total net revenue
  • Prior-quarter operating expenses
  • Prior-quarter net non-operating income
  • Prior-quarter net loss
  • Prior-quarter net loss per share
  • Percentage changes for total net revenue, operating expenses, net loss, net loss per share, and cash
  • Operating cash flow
  • Free cash flow
  • Debt
  • Dividends
  • Share repurchases
  • Segment revenue
  • Forward revenue guidance
  • Forward gross-margin guidance
  • Forward operating-expense guidance
  • Forward tax-rate guidance
  • Prior outlook for comparison

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about EYPT earnings dates

When is EyePoint's next earnings date?
AlphAI has no date for EYPT yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.